CLINICAL_TRIALS ClinicalTrials.gov record update

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07315087
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:37.483779+00:00
Published At: 2026-01-20T00:00:00+00:00
Record Updated At: 2026-01-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["SLE - Systemic Lupus Erythematosus", "SSc-Systemic Sclerosis", "IIM- Idiopathic Inflammatory Myopathies", "ANCA Associated Vasculitis (AAV)", "Connective Tissue Disease-Associated Thrombocytopenia", "SLE-ITP"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-20"
protocolSection.identificationModule.nctId: "NCT07315087"
protocolSection.identificationModule.officialTitle: "A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.